MRD testing after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This study looks at whether a blood test for leftover cancer cells (called MRD) after stomach cancer surgery can help guide treatment. It is for people with a certain type of stomach cancer that has spread to nearby tissues but not to distant organs, and who are having surgery as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of stomach cancer (adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma).
- Your tumor is stage T4 (has spread to nearby tissues) but has not spread to distant organs, and you are scheduled for surgery to remove it.
- You are between 18 and 75 years old.
- You are physically active and able to care for yourself (ECOG score 0 or 1).
- You have not had chemotherapy or radiation before surgery, and you and your family prefer surgery first.
- Your blood counts and liver/kidney function are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving personalized follow-up treatment after stomach cancer surgery and chemotherapy can help prevent the cancer from coming back. The treatment plan is tailored based on how well the tumor responded to initial chemotherapy.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
This study watches for signs of leftover cancer after surgery using a blood test (MRD). It is for people with early-stage colon cancer who have not yet had any treatment other than surgery.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.